Keywords
Anti-Inflammatory Agents
Interleukin Inhibitors
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To evaluate the efficacy of emerging anti-inflammatory therapies, such as interleukin inhibitors, in reducing the progression of atherosclerosis and preventing cardiovascular events in patients with atherosclerosis. Methods: Integrative review using the Pubmed database platform. The search was carried out using the following search strategy: (("Anti-Inflammatory Agents"[MeSH]) OR ("Interleukin Inhibitors"[MeSH])) AND (Atherosclerosis). A total of 664 articles were found in the database after applying the search strategies. After applying the inclusion and exclusion criteria, 60 articles were selected and 41 articles were removed after the initial analysis. This left a total of 19 articles for full analysis. Results: It is clear that anti-inflammatory therapies have the potential to improve the prognosis of patients with atherosclerosis, but there are still issues such as side effects, the cost of medication and long-term efficacy. Final considerations: Notable progress in understanding the mechanisms underlying inflammation in atherosclerosis and in the development of therapeutic strategies targeting them have considerable potential for reducing the progression of atherosclerosis and preventing cardiovascular events in patients with atherosclerosis.
References
ALLAM G, et al. The pleiotropic role of interleukin-17 in atherosclerosis. Biomedicine & Pharmacotherapy, 2018; 106: 1412-1418.
CHAN YH e RAMJI DP. A perspective on targeting inflammation and cytokine actions in atherosclerosis. Future Med Chem, 2020;12(7):613-626.
CHEN S, et al. Novel Role for Tranilast in Regulating NLRP3 Ubiquitination, Vascular Inflammation, and Atherosclerosis. J Am Heart Assoc. 2020;9(12):e015513.
GAO W, et al. Reductively dissociable biomimetic nanoparticles for control of integrin-coupled inflammatory signaling to retard atherogenesis. Chem Commun (Camb). 2019 Sep 24;55(77):11535-11538.
GASPAROTTO FM, et al. Antiatherosclerotic Properties of Echinodorus grandiflorus (Cham. & Schltdl.) Micheli: From Antioxidant and Lipid-Lowering Effects to an Anti-Inflammatory Role. J Med Food, 2019;22(9):919-927.
GEORGAKIS MK, et al. Targeting the CCL2-CCR2 axis for atheroprotection. Eur Heart J, 2022;43(19):1799-1808.
GLUBA-BRZÓZKA A, et al. Emerging anti-atherosclerotic therapies. International Journal of Molecular Sciences. 2021; 22(22), 12109.
GONG C, et al. Parecoxib improves atherosclerotic plaque stability by suppressing inflammation and inhibiting matrix metalloproteinases production. Biomedicine & Pharmacotherapy, 2021; 138: 111423.
HERVÁS SM e NAVARRO HG. Anti-inflammatory Therapies for Cardiovascular Disease: Signaling Pathways and Mechanisms. Revista Española de Cardiologia, 2019; 72: 767-773.
JEON S, et al. Anti-Inflammatory Actions of Soluble Ninjurin-1 Ameliorate Atherosclerosis. Circulation, 2020; 142(18):1736-1751.
KHAMBHATI J, et al. Immunotherapy for the prevention of atherosclerotic cardiovascular disease: Promise and possibilities. Atherosclerosis. 2018 Sep;276:1-9.
KOTTOOR SJ e ARORA RR. The utility of anti-inflammatory agents in cardiovascular disease: a novel perspective on the treatment of atherosclerosis. Journal of cardiovascular pharmacology and therapeutics, 2018; 23(6), 483-493.
KOUSHKI K, et al. Anti-inflammatory Action of Statins in Cardiovascular Disease: the Role of Inflammasome and Toll-Like Receptor Pathways. Clin Rev Allergy Immunol, 2021;60(2):175-199.
LIBBY P e EVERETT BM. Novel Antiatherosclerotic Therapies. Arterioscler Thromb Vasc Biol. 2019;39(4):538-545.
LIU W, et al. Interleukin-23: A New Atherosclerosis Target. Journal of interferon & cytokine research, 2018; 38(10), 440-444.
LUO P, et al. Bazedoxifene exhibits anti-inflammation and anti-atherosclerotic effects via inhibition of IL-6/IL-6R/STAT3 signaling. European Journal of Pharmacology, 2021; 893:173822.
MCCURDY S, et al. Potential role of IL-37 in atherosclerosis. Cytokine, 2019;122:154169.
MENG Q, et al. Morin hydrate inhibits atherosclerosis and LPS-induced endothelial cells inflammatory responses by modulating the NFκB signaling-mediated autophagy. International Immunopharmacol, 2021; 100:108096.
POZNYAK AV, et al. Anti-inflammatory therapy for atherosclerosis: focusing on cytokines. International journal of molecular sciences, 2021; 22(13), 7061.
RIDKER PM. From Rescue to Zeus: will interleukin-6 inhibition with ziltivekimab prove effective for cardiovascular event reduction? Published on behalf of the European Society of Cardiology, 2021; 117, e138–e140.
SOEHNLEIN O e LIBBY P. Targeting inflammation in atherosclerosis—from experimental insights to the clinic. Nature reviews Drug discovery, 2021; 20(8), 589-610.
STERPETTI AV. Inflammatory Cytokines and Atherosclerotic Plaque Progression. Therapeutic Implications. Curr Atheroscler Rep, 2020; 22:75: 1-12
WACINSKI P, et al. Anti-Inflammatory Effect of Very High Dose Local Vessel Wall Statin Administration: Poly(L,L-Lactide) Biodegradable Microspheres with Simvastatin for Drug Delivery System (DDS). International Journal of Molecular Sciences, 2021; 22(14), 7486.
WANG Y, et al. Targeted therapy of atherosclerosis by a broad-spectrum reactive oxygen species scavenging nanoparticle with intrinsic anti-inflammatory activity. ACS nano, 2018; 12.9 : 8943-8960.
YU J, et al. IMM-H007, a novel small molecule inhibitor for atherosclerosis, represses endothelium inflammation by regulating the activity of NF-κB and JNK/AP1 signaling. Toxicol Appl Pharmacol. 2019 Oct 15;381:114732.